Related Experiment Videos
Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion
C U Ludwig1, R Ludwig-Hagemann, R Obrist
1Department of Internal Medicine, The University, Kantonsspital Basle, Switzerland.
Onkologie
|April 1, 1990
Summary
Continuous subcutaneous infusion of Interferon (IFN) alpha-2a demonstrated safety and efficacy in patients with advanced cancers. This method achieved significant serum levels with manageable side effects, showing potential for combination therapies.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Interferon (IFN) alpha-2a is a biologic response modifier used in cancer treatment.
- Previous administration routes (intermittent i.m. or s.c.) have limitations.
- Continuous subcutaneous infusion offers a novel administration method.
Purpose of the Study:
- To evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of continuous subcutaneous infusion of IFN alpha-2a.
- To determine optimal dosing for this administration route.
- To explore the potential of this method for future combination therapies.
Main Methods:
- Phase I clinical trial involving 15 patients with progressing melanomas, hypernephromas, or B-cell malignancies.
- Daily administration of IFN alpha-2a (12-15 MU) via syringe driver pump.
- Monitoring of side effects, toxicity, serum levels (EIA-F-assay), and tumor response.
Main Results:
- Daily doses of 12-15 MU were safely administered, with median weekly doses of 90 MU.
- Main toxicities included reversible leukopenia, flu-like symptoms, and gastrointestinal issues (mostly grade 1 or 2).
- Median serum IFN alpha-2a levels reached 54 IU/ml, with one partial tumor regression and four disease stabilizations observed.
Conclusions:
- Continuous subcutaneous infusion of IFN alpha-2a is a safe and tolerable method for treating advanced malignancies.
- This route achieves significant and sustained serum concentrations with minimal side effects.
- The findings support further investigation of continuous IFN alpha-2a infusion, potentially in combination with other immunomodulatory agents.